Development of an HPV vaccine for a broad spectrum of high-risk types

Human Vaccines

Volumn 5, Issue 1, 2009, Pages 43-45

  Kanda, Tadahito ^a   Kondo, Kazunari ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

High risk HPV; Minor capsid protein L2; Type common neutralization epitope; VLP vaccine

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; CAPSID PROTEIN L2; CHIMERIC PROTEIN; EPITOPE; NEUTRALIZING ANTIBODY; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS DNA; WART VIRUS VACCINE; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ACTIVE IMMUNIZATION; ARTICLE; BOVINE PAPILLOMAVIRUS TYPE 4; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; NONHUMAN; PREVALENCE; RABBIT; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VIRION; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS REPLICATION; ANIMAL; GENETICS; IMMUNOLOGY; VIROLOGY; VIRUS INFECTION;

ANIMALS; CAPSID PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RABBITS;

EID: 63349100502     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.1.6554     Document Type: Article

References (22)

1. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC Press 2004.
2. Munoz N, Bosch FX, Castellsague X, Diaz M, Sanjose S, Hammouda D, Shah KV, Meijer CJLM. Against which human papillomavirus types shall we vaccinate and screen? Int J Cancer 2004; 111:278-85.
3. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24:26-34.
4. Zur Hausen H. Papillomavirus infections-A major cause of human cancers. Biochem Biopys Acta 1996; 1288:55-78.
5. Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92:690-8.
6. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. Arrangement of L2 within the papillomavirus capsid. J Virol 2008; 82:5190-7.
7. Kirnbauer R, Taub J, Greenstone H, Roden R, Duerst M, Gissmann L, Lowy DR, Schiller JT. Efficient self-assembly of human papillomavirus type 16 and L1-L2 into virus-like particles. J Virol 1993; 67:6929-36.
8. Volpers C, Schirmacher P, Streeck R, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994; 200:504-12.
9. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78:751-7.
10. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald DC, Kruger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16.
11. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89:12180-4.
12. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type16 vaccine. N Engl J Med 2004; 347:1645-51.
13. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19:1783-93.
14. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219:37-44.
15. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FF, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 2005; 6:271-8.
16. Harper DM, Franco DM, Wheeler CM, Moscocki AB, Romanoswski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. HPV vaccine study group, 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-55.
17. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. Neutralization of HPV16, 18, 31 and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007; 358:266-72.
18. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007; 81:13927-31.
19. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses immunization with short peptides of L2, the minor capsid protein. J Virol 2002; 76:9798-805.
20. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 1996; 77:1577-83.
21. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RBS. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminal of minor antigen L2. J Virol 2007; 81:11585-92.
22. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitope. J Med Virol 2008; 80:841-6.